Compare MYO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | PMN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 34.6M |
| IPO Year | 2017 | 2022 |
| Metric | MYO | PMN |
|---|---|---|
| Price | $0.68 | $21.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 367.8K | 48.4K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | N/A |
| Revenue This Year | $24.07 | N/A |
| Revenue Next Year | $17.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.64 | $0.29 |
| 52 Week High | $6.27 | $27.40 |
| Indicator | MYO | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 65.90 |
| Support Level | $0.64 | $0.43 |
| Resistance Level | $1.03 | N/A |
| Average True Range (ATR) | 0.06 | 2.69 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 23.90 | 59.68 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.